Compare Alcon AG (ALC) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Lufax Holding Ltd — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Lufax Holding Ltd trades at $1.41 (market cap $2.41B). The key difference: Alcon AG is far larger — about 13.6× Lufax Holding Ltd's market cap, and Alcon AG pays a 0.54% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| ALC | LU | |
|---|---|---|
Market Cap | $32.69B | $2.41B |
Sector | Health | Technology |
52-Week High | $92.22 | $4.40 |
52-Week Low | $62.02 | $1.23 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
LU trades at $1.42, up 1.43% today, with a bullish technical signal but bearish moving averages. The stock shows deep value with a P/S of 0.36 and P/B of 0.1, yet profitability is weak with a -9.08% net margin and negative ROE. Recent news is dominated by a securities class action lawsuit with a May 20, 2026 deadline, creating significant headline risk.
The outlook is mixed; low valuations and a bullish analyst consensus (61.5% buy ratings) suggest potential upside, but negative earnings, cash flow challenges, and legal overhang present substantial risks. Investor sentiment is cautious due to the litigation, making near-term performance highly dependent on case developments and future earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
